flâneur

New HIV vaccine shows unprecedented success in preclinical study – lji.org

lji.org · 1,732 words · saved by 1 readers

LA JOLLA, CA—A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists, and IAVI has the potential to protect humans from developing HIV infection and AIDS. This HIV vaccine is the first to generate a high number of “broadly neutralizing,” virus-fighting antibodies in primates. “This feels like a huge success,” says LJI Professor and Chief Scientific Officer Shane Crotty, Ph.D., who co-led the research with Scripps Research Professor William Schief, Ph.D. “We constructed a successful vaccine from the ground up, which required a deep understanding of the immune system.” This groundbreaking research, published in Nature, is the result of 14 years of collaboration between La Jolla Institute for Immunology and Scripps Research, as part of the Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD). “This has been one of those Apollo moon mission-type projects, where there is an exceptional goal and the team has to accomplish a myriad of discove

New HIV vaccine shows unprecedented success in preclinical study – lji.org Skip to content Skip to content New HIV vaccine shows unprecedented success in preclinical study Vaccine approach yields high numbers of HIV-neutralizing antibodies in non-human primates Madeline McCurry-Schmidt Science Writer July 6, 2026 Share this Article: Highlights: Scientists at La Jolla Institute for Immunology, Scripps Research have developed an HIV vaccine that trains immune cells to see past HIV’s defenses. This HIV vaccine works by prompting the body’s immune system to make substantial numbers of rarely

saved by

related reading